Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/12/2024 | Buy → Hold | Stifel | |
| 1/31/2022 | $6.90 | Equal-Weight | Morgan Stanley |
| 11/23/2021 | $16.00 | Buy | Stifel |
| 11/23/2021 | $15.00 | Buy | B of A Securities |
| 11/23/2021 | $30.00 | Buy | Goldman Sachs |
| 11/23/2021 | $17.00 | Overweight | Piper Sandler |
Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights Generated $8.0 million total revenue for the third quarter of 2024 and carried over a double-digit console backlog for the third straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 41.2% and 42.6%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $7.5 million and adjusted EBITDA (non-GAAP) loss to $5.1 million, a 57% and
Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca
Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th
John Bostjancic Appointed as Chief Financial Officer Bob Guyatt Appointed as Senior Vice President of Marketing John McGaugh Promoted to Senior Vice President of Operations Sonendo, Inc. (OTCQX:SONX) ("Sonendo"), a leading dental technology company and developer of the GentleWave® System, today announced the appointment of John Bostjancic as Chief Financial Officer, the appointment of Robert Guyatt as Senior Vice President of Marketing, and the promotion of John McGaugh to Senior Vice President of Operations. "Sonendo is embarking on a reset strategy to drive fundamental change within the organization," said Bjarne Bergheim, President and Chief Executive Officer of Sonendo. "We have fil
The Partnership Agreements Aim to Increase the Number of Endodontic Practices Offering the GentleWave System Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced the signing of two new strategic partnership agreements with the country's leading endodontic dental service organizations (DSOs) to expand patient access to a best-in-class root canal experience. As a result of these partnerships, the GentleWave System with CleanFlow™ Technology, which offers a less invasive and less painful alternative to traditional root canal therapy, will be available in more endodontic offices nationwide. Sonendo previously announced the a
Sonendo, Inc. (NYSE:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that on September 25, 2023, the Compensation Committee of Sonendo's Board of Directors granted restricted stock unit awards covering an aggregate of 14,000 shares of its common stock to two new, non-executive employees to induce them to join the company. The awards were granted under Sonendo's 2023 Employment Inducement Incentive Award Plan (the "Inducement Plan"), which was adopted on March 2, 2023 and provides for the granting of equity awards to prospective employees of Sonendo under NYSE Listing Rule 303A.08. The restricted stock unit awards vest over a four-year p
10-Q - Sonendo, Inc. (0001407973) (Filer)
8-K - Sonendo, Inc. (0001407973) (Filer)
8-K - Sonendo, Inc. (0001407973) (Filer)
Stifel downgraded Sonendo from Buy to Hold
Morgan Stanley initiated coverage of Sonendo with a rating of Equal-Weight and set a new price target of $6.90
Stifel initiated coverage of Sonendo with a rating of Buy and set a new price target of $16.00
Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that management will postpone the third quarter 2024 conference call that was previously scheduled for after the market close on Tuesday, November 12th, 2024. The Company still intends to file its audited financial results on November 12th, 2024, but has postponed, until further notice, the accompanying conference call. Management will provide commentary on events subsequent to the end of the quarter ending September 30th, 2024, at a later date. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth deca
Sonendo, Inc. ("Sonendo") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today announced that it will report financial results for the third quarter 2024 after the market close on Tuesday, November 12th, 2024. Management will host a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results. Investors interested in listening to the conference call may do so by dialing (833) 470-1428 for domestic callers or (404) 975-4839 for international callers, using access code: 788725. Live audio of the webcast will be available at: https://investor.sonendo.com. An archived recording will be available on th
Sonendo, Inc. ("Sonendo" or the "Company") (OTCQX:SONX), a leading dental technology company and developer of the GentleWave® System, today reported financial results for the second quarter ended June 30, 2024. Recent Highlights Generated $8.3 million total revenue for second quarter of 2024 and carried over a healthy console backlog for the second straight quarter; Drove substantial increases in GAAP gross margin and adjusted gross margins (non-GAAP) to 37.5% and 40.7%, respectively, based primarily on lower manufacturing and console warranty costs; Significantly reduced GAAP operating loss to $6.7 million and adjusted EBITDA (non-GAAP) loss to $5.7 million, a 61% and 55% improv
4 - Sonendo, Inc. (0001407973) (Issuer)
4 - Sonendo, Inc. (0001407973) (Issuer)
4 - Sonendo, Inc. (0001407973) (Issuer)
SC 13G/A - Sonendo, Inc. (0001407973) (Subject)
SC 13G - Sonendo, Inc. (0001407973) (Subject)
SC 13G/A - Sonendo, Inc. (0001407973) (Subject)
4 - Sonendo, Inc. (0001407973) (Issuer)
4 - Sonendo, Inc. (0001407973) (Issuer)
4 - Sonendo, Inc. (0001407973) (Issuer)
Sonendo (NYSE:SONX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $0.09 by 177.78 percent. This is a 56.25 percent increase over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $7.047 million which beat the analyst consensus estimate of $6.300 million by 11.86 percent. This is a 18.79 percent decrease over sales of $8.678 million the same period last year.
Stifel analyst Jonathan Block downgrades Sonendo (OTC:SONX) from Buy to Hold and lowers the price target from $1 to $0.25.
Sonendo (NYSE:SONX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 14.29 percent. This is unchanged from the same period last year. The company reported quarterly sales of $11.69 million which missed the analyst consensus estimate of $11.80 million by 0.92 percent. This is a 4.40 percent decrease over sales of $12.23 million the same period last year.